Cullinan Associates Inc. boosted its stake in Eli Lilly and Co (NYSE:LLY) by 3.9% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 34,567 shares of the company’s stock after acquiring an additional 1,300 shares during the quarter. Cullinan Associates Inc.’s holdings in Eli Lilly and were worth $2,920,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently added to or reduced their stakes in the stock. Acrospire Investment Management LLC boosted its stake in Eli Lilly and by 16.7% during the 2nd quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the last quarter. MPS Loria Financial Planners LLC acquired a new stake in Eli Lilly and during the 2nd quarter worth $128,000. San Francisco Sentry Investment Group CA acquired a new stake in Eli Lilly and during the 2nd quarter worth $129,000. Willingdon Wealth Management acquired a new stake in Eli Lilly and during the 3rd quarter worth $138,000. Finally, Wealthcare Advisory Partners LLC acquired a new stake in Eli Lilly and during the 3rd quarter worth $142,000. 76.35% of the stock is currently owned by hedge funds and other institutional investors.
Several brokerages have issued reports on LLY. Morgan Stanley set a $86.00 target price on shares of Eli Lilly and and gave the stock a “hold” rating in a research note on Friday, October 6th. Leerink Swann lifted their target price on shares of Eli Lilly and from $92.00 to $93.00 and gave the stock a “market perform” rating in a research note on Monday, October 23rd. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the stock a “sell” rating in a research note on Tuesday, October 24th. Credit Suisse Group cut shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and lifted their target price for the stock from $84.23 to $88.00 in a research note on Tuesday, October 10th. Finally, Goldman Sachs Group cut shares of Eli Lilly and from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $86.98 to $95.00 in a research note on Tuesday. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $92.75.
In related news, major shareholder Lilly Endowment Inc sold 200,000 shares of the business’s stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total value of $17,640,000.00. Following the sale, the insider now directly owns 123,084,104 shares in the company, valued at approximately $10,856,017,972.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the business’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the sale, the senior vice president now owns 43,580 shares in the company, valued at $3,646,338.60. The disclosure for this sale can be found here. In the last quarter, insiders have sold 251,088 shares of company stock worth $22,041,236. Insiders own 0.20% of the company’s stock.
Eli Lilly and Co (NYSE LLY) opened at $86.21 on Thursday. Eli Lilly and Co has a fifty-two week low of $74.00 and a fifty-two week high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $93,912.40, a price-to-earnings ratio of 40.86, a PEG ratio of 1.60 and a beta of 0.35.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping the consensus estimate of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business had revenue of $5.66 billion for the quarter, compared to analyst estimates of $5.52 billion. During the same quarter in the previous year, the firm earned $0.88 EPS. The company’s quarterly revenue was up 9.0% compared to the same quarter last year. research analysts expect that Eli Lilly and Co will post 4.22 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 annualized dividend and a dividend yield of 2.61%. The ex-dividend date of this dividend is Wednesday, February 14th. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s payout ratio is currently 98.58%.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/18/eli-lilly-and-co-lly-shares-bought-by-cullinan-associates-inc.html.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.